Acquired resistance to tyrosine kinase inhibitors during cancer therapy.

Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer (2009) 12.92

Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell (2010) 12.50

Cell signaling by receptor tyrosine kinases. Cell (2010) 12.39

Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. Sci Transl Med (2012) 8.41

Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol (2011) 8.37

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature (2012) 8.13

The PI3K pathway as drug target in human cancer. J Clin Oncol (2010) 6.83

Targeting the TGFβ signalling pathway in disease. Nat Rev Drug Discov (2012) 4.30

Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition. Proc Natl Acad Sci U S A (2009) 4.02

Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc Natl Acad Sci U S A (2011) 3.97

Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. Nat Rev Drug Discov (2009) 3.64

Therapy-induced tumour secretomes promote resistance and tumour progression. Nature (2015) 3.07

Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. Sci Transl Med (2010) 2.86

Evolutionary dynamics of carcinogenesis and why targeted therapy does not work. Nat Rev Cancer (2012) 2.71

A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. Cancer Discov (2013) 2.49

EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy. Sci Signal (2009) 2.23

Spherical nucleic acid nanoparticle conjugates as an RNAi-based therapy for glioblastoma. Sci Transl Med (2013) 1.99

Acquired resistance of non-small cell lung cancer cells to MET kinase inhibition is mediated by a switch to epidermal growth factor receptor dependency. Cancer Res (2010) 1.94

Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer. J Clin Oncol (2013) 1.88

MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors. Cancer Res (2012) 1.87

Complexities of TGF-β targeted cancer therapy. Int J Biol Sci (2012) 1.84

Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA. Cancer Discov (2014) 1.77

Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors. Cancer Res (2011) 1.67

Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition. J Exp Med (2012) 1.65

A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer. Naunyn Schmiedebergs Arch Pharmacol (2014) 1.63

Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy. Mol Cancer (2010) 1.56

Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils. EMBO Mol Med (2011) 1.52

Targeting ALK in neuroblastoma--preclinical and clinical advancements. Nat Rev Clin Oncol (2012) 1.42

Targeting the disordered C terminus of PTP1B with an allosteric inhibitor. Nat Chem Biol (2014) 1.40

Chemosensitization of cancer cells by siRNA using targeted nanogel delivery. BMC Cancer (2010) 1.31

Mechanisms of drug resistance in kinases. Expert Opin Investig Drugs (2011) 1.29

Targeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance. Curr Cancer Drug Targets (2012) 1.21

p53 modulates acquired resistance to EGFR inhibitors and radiation. Cancer Res (2011) 1.17

Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition. Mol Cancer (2010) 1.14

Targeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges. J Oncol (2009) 1.12

Translational implications of tumor heterogeneity. Clin Cancer Res (2015) 1.12

Emerging importance of ALK in neuroblastoma. Semin Cancer Biol (2011) 1.10

Acquired MET expression confers resistance to EGFR inhibition in a mouse model of glioblastoma multiforme. Oncogene (2011) 1.07

Ten things you should know about protein kinases: IUPHAR Review 14. Br J Pharmacol (2015) 1.06

Current Therapeutic Advances Targeting EGFR and EGFRvIII in Glioblastoma. Front Oncol (2015) 1.05

Differences underlying EGFR and HER2 oncogene addiction. Cell Cycle (2010) 1.02

Antibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastoma. Oncogene (2012) 1.01

Emerging molecular classifications and therapeutic implications for gastric cancer. Chin J Cancer (2016) 1.00

Role of erlotinib in first-line and maintenance treatment of advanced non-small-cell lung cancer. Cancer Manag Res (2010) 0.98

PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations. Proc Natl Acad Sci U S A (2015) 0.97

Hsp90 as a gatekeeper of tumor angiogenesis: clinical promise and potential pitfalls. J Oncol (2010) 0.97

Genetic modifiers of EGFR dependence in non-small cell lung cancer. Proc Natl Acad Sci U S A (2014) 0.97

A growing family: adding mutated Erbb4 as a novel cancer target. Cell Cycle (2010) 0.95

PI3K and AKT: Unfaithful Partners in Cancer. Int J Mol Sci (2015) 0.92

JAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasms. JAKSTAT (2013) 0.91

A novel proteomics-based clinical diagnostics technology identifies heterogeneity in activated signaling pathways in gastric cancers. PLoS One (2013) 0.90

Relevance of MET activation and genetic alterations of KRAS and E-cadherin for cetuximab sensitivity of gastric cancer cell lines. J Cancer Res Clin Oncol (2012) 0.88

Resistance of Cancer Cells to Targeted Therapies Through the Activation of Compensating Signaling Loops. Curr Signal Transduct Ther (2013) 0.88

Activation of HER3 interferes with antitumor effects of Axl receptor tyrosine kinase inhibitors: suggestion of combination therapy. Neoplasia (2014) 0.87

Berbamine inhibits proliferation and induces apoptosis of KU812 cells by increasing Smad3 activity. J Zhejiang Univ Sci B (2011) 0.87

RAS/MAPK Activation Drives Resistance to Smo Inhibition, Metastasis, and Tumor Evolution in Shh Pathway-Dependent Tumors. Cancer Res (2015) 0.87

Therapeutic targeting of the phosphatidylinositol 3-kinase signaling pathway: novel targeted therapies and advances in the treatment of colorectal cancer. Therap Adv Gastroenterol (2012) 0.86

Chronic activation of wild-type epidermal growth factor receptor and loss of Cdkn2a cause mouse glioblastoma formation. Cancer Res (2011) 0.85

Pharmacogenomics of EGFR-targeted therapies in non-small cell lung cancer: EGFR and beyond. Chin J Cancer (2015) 0.85

The isomerase PIN1 controls numerous cancer-driving pathways and is a unique drug target. Nat Rev Cancer (2016) 0.84

Receptor tyrosine kinases with intracellular pseudokinase domains. Biochem Soc Trans (2013) 0.84

Tumour heterogeneity and immune-modulation. Curr Opin Pharmacol (2013) 0.84

The latest therapeutic strategies after resistance to first generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in patients with non-small cell lung cancer (NSCLC). Ann Transl Med (2015) 0.84

Gefitinib-resistance is related to BIM expression in non-small cell lung cancer cell lines. Cancer Biother Radiopharm (2012) 0.83

Sonic hedgehog signaling in Basal cell nevus syndrome. Cancer Res (2014) 0.83

CYP3A activity influences imatinib response in patients with chronic myeloid leukemia: a pilot study on in vivo CYP3A activity. Eur J Clin Pharmacol (2010) 0.83

Grape polyphenols inhibit Akt/mammalian target of rapamycin signaling and potentiate the effects of gefitinib in breast cancer. Nutr Cancer (2012) 0.83

Targeting heat shock protein 90 for the treatment of malignant pheochromocytoma. PLoS One (2013) 0.82

Anti-EGFR therapeutic efficacy correlates directly with inhibition of STAT3 activity. Cancer Biol Ther (2014) 0.81

Excessive MET signaling causes acquired resistance and addiction to MET inhibitors in the MKN45 gastric cancer cell line. Invest New Drugs (2013) 0.81

Emerging anti-cancer antibodies and combination therapies targeting HER3/ERBB3. Hum Vaccin Immunother (2015) 0.81

Toward personalized cancer nanomedicine - past, present, and future. Integr Biol (Camb) (2013) 0.80

NVP-BEZ235 overcomes gefitinib-acquired resistance by down-regulating PI3K/AKT/mTOR phosphorylation. Onco Targets Ther (2015) 0.80

Tyrosine kinase inhibitors in lung cancer. Hematol Oncol Clin North Am (2012) 0.80

Truncated RAF kinases drive resistance to MET inhibition in MET-addicted cancer cells. Oncotarget (2015) 0.80

Nanomolar-Potency Small Molecule Inhibitor of STAT5 Protein. ACS Med Chem Lett (2014) 0.80

Chemotherapeutic Targeting of the Transforming Growth Factor-β Pathway in Breast Cancers. Breast Cancer Manag (2015) 0.79

Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC. Front Oncol (2016) 0.79

Humanized anti-hepatocyte growth factor (HGF) antibody suppresses innate irinotecan (CPT-11) resistance induced by fibroblast-derived HGF. Oncotarget (2015) 0.79

How to Use a Chemotherapeutic Agent When Resistance to It Threatens the Patient. PLoS Biol (2017) 0.79

Cetuximab-modified mesoporous silica nano-medicine specifically targets EGFR-mutant lung cancer and overcomes drug resistance. Sci Rep (2016) 0.79

New therapeutic strategies in neuroblastoma: combined targeting of a novel tyrosine kinase inhibitor and liposomal siRNAs against ALK. Oncotarget (2015) 0.78

Anchor-based classification and type-C inhibitors for tyrosine kinases. Sci Rep (2015) 0.78

Preclinical Efficacy of Ron Kinase Inhibitors Alone and in Combination with PI3K Inhibitors for Treatment of sfRon-Expressing Breast Cancer Patient-Derived Xenografts. Clin Cancer Res (2015) 0.78

Resistance to the c-Met inhibitor KRC-108 induces the epithelial transition of gastric cancer cells. Oncol Lett (2015) 0.78

Cytomegalovirus-induced salivary gland pathology: resistance to kinase inhibitors of the upregulated host cell EGFR/ERK pathway is associated with CMV-dependent stromal overexpression of IL-6 and fibronectin. Herpesviridae (2013) 0.77

Induction of multiple drug resistance in HMEC-1 endothelial cells after long-term exposure to sunitinib. Onco Targets Ther (2014) 0.77

Allosteric modulators can restore function in an amino acid neurotransmitter receptor by slightly altering intra-molecular communication pathways. Br J Pharmacol (2012) 0.77

ERRα mediates metabolic adaptations driving lapatinib resistance in breast cancer. Nat Commun (2016) 0.76

Polyclonal immune responses to antigens associated with cancer signaling pathways and new strategies to enhance cancer vaccines. Immunol Res (2011) 0.76

Effects of tyrosine kinase inhibitor E7080 and eNOS inhibitor L-NIO on colorectal cancer alone and in combination. Chin J Cancer Res (2013) 0.76

Rapid Identification of Chemoresistance Mechanisms Using Yeast DNA Mismatch Repair Mutants. G3 (Bethesda) (2015) 0.76

Functional screening implicates miR-371-3p and peroxiredoxin 6 in reversible tolerance to cancer drugs. Nat Commun (2016) 0.75

Direct pharmacological assessment of clinically acquired models as a strategy to overcome resistance to tyrosine kinase inhibitors. Mol Cell Oncol (2015) 0.75

Small-Molecule Procaspase-3 Activation Sensitizes Cancer to Treatment with Diverse Chemotherapeutics. ACS Cent Sci (2016) 0.75

Gene-expression profiles in lung adenocarcinomas related to chronic wood smoke or tobacco exposure. Respir Res (2016) 0.75

Mitochondrial-Targeting MET Kinase Inhibitor Kills Erlotinib-Resistant Lung Cancer Cells. ACS Med Chem Lett (2016) 0.75

Development of an in vitro model of acquired resistance to toceranib phosphate (Palladia®) in canine mast cell tumor. BMC Vet Res (2014) 0.75

Steering tumor progression through the transcriptional response to growth factors and stroma. FEBS Lett (2014) 0.75

Registered report: A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Elife (2016) 0.75

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med (2010) 36.78

Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy (2007) 20.92

Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature (2012) 15.91

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol (2009) 15.23

Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer (2007) 14.84

Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med (2008) 13.54

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science (2004) 11.58

First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol (2008) 9.43

Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc Natl Acad Sci U S A (2007) 8.23

Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci U S A (2005) 6.82

Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res (2008) 6.71

Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Mol Med (2010) 6.38

Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res (2008) 6.05

Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci U S A (2006) 5.23

Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat Genet (2008) 5.07

EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov (2012) 4.72

p120-catenin and p190RhoGAP regulate cell-cell adhesion by coordinating antagonism between Rac and Rho. Cell (2006) 4.24

Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev (2007) 4.11

A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes. Cancer Cell (2006) 3.78

SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature (2011) 3.69

Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. Cancer Cell (2012) 3.39

Modulation of Rho GTPase signaling regulates a switch between adipogenesis and myogenesis. Cell (2003) 3.36

BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation. Sci Signal (2010) 3.25

Oncogenic activity of epidermal growth factor receptor kinase mutant alleles is enhanced by the T790M drug resistance mutation. Cancer Res (2007) 2.78

Androgen deprivation causes epithelial-mesenchymal transition in the prostate: implications for androgen-deprivation therapy. Cancer Res (2011) 2.71

Transitions between epithelial and mesenchymal states in development and disease. Semin Cell Dev Biol (2008) 2.69

The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor. Mol Cancer Ther (2008) 2.58

STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis. Cancer Res (2011) 2.35

Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib. Cancer Res (2007) 2.30

"Oncogenic shock": explaining oncogene addiction through differential signal attenuation. Clin Cancer Res (2006) 2.30

GAP control: regulating the regulators of small GTPases. Trends Cell Biol (2004) 2.21

Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers. J Clin Invest (2011) 2.20

Inhibition of gamma-secretase activity inhibits tumor progression in a mouse model of pancreatic ductal adenocarcinoma. Gastroenterology (2009) 2.17

Rnd proteins function as RhoA antagonists by activating p190 RhoGAP. Curr Biol (2003) 1.84

Opposing functions of TFII-I spliced isoforms in growth factor-induced gene expression. Mol Cell (2006) 1.81

Modeling oncogene addiction using RNA interference. Proc Natl Acad Sci U S A (2008) 1.79

The complexity of targeting EGFR signalling in cancer: from expression to turnover. Biochim Biophys Acta (2006) 1.75

TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma. Sci Transl Med (2013) 1.67

Modulation of CREB activity by the Rho GTPase regulates cell and organism size during mouse embryonic development. Dev Cell (2002) 1.58

Potential therapeutic strategies to overcome acquired resistance to BRAF or MEK inhibitors in BRAF mutant cancers. Oncotarget (2011) 1.55

Ligand-dependent platelet-derived growth factor receptor (PDGFR)-alpha activation sensitizes rare lung cancer and sarcoma cells to PDGFR kinase inhibitors. Cancer Res (2009) 1.54

Integrin signaling through Arg activates p190RhoGAP by promoting its binding to p120RasGAP and recruitment to the membrane. Mol Biol Cell (2006) 1.54

Activated Kras, but not Hras or Nras, may initiate tumors of endodermal origin via stem cell expansion. Mol Cell Biol (2008) 1.53

SHP-2 positively regulates myogenesis by coupling to the Rho GTPase signaling pathway. Mol Cell Biol (2004) 1.53

A structure-guided approach to creating covalent FGFR inhibitors. Chem Biol (2010) 1.46

Activation of PI3K signaling in Merkel cell carcinoma. Clin Cancer Res (2012) 1.45

p190RhoGAP is the convergence point of adhesion signals from alpha 5 beta 1 integrin and syndecan-4. J Cell Biol (2008) 1.41

Inhibition of Rho via Arg and p190RhoGAP in the postnatal mouse hippocampus regulates dendritic spine maturation, synapse and dendrite stability, and behavior. J Neurosci (2007) 1.33

Adhesion-dependent regulation of p190RhoGAP in the developing brain by the Abl-related gene tyrosine kinase. Curr Biol (2004) 1.30

Genetic interactions between Drosophila melanogaster Atg1 and paxillin reveal a role for paxillin in autophagosome formation. Autophagy (2007) 1.30

A kinase shRNA screen links LATS2 and the pRB tumor suppressor. Genes Dev (2011) 1.30

Isoform-specific ras functions in development and cancer. Future Oncol (2009) 1.29

A chemical biology approach to developing STAT inhibitors: molecular strategies for accelerating clinical translation. Oncotarget (2011) 1.26

Mutational activation of ErbB family receptor tyrosine kinases: insights into mechanisms of signal transduction and tumorigenesis. Bioessays (2007) 1.26

Breast tumor kinase phosphorylates p190RhoGAP to regulate rho and ras and promote breast carcinoma growth, migration, and invasion. Cancer Res (2008) 1.26

Targeting aberrant glutathione metabolism to eradicate human acute myelogenous leukemia cells. J Biol Chem (2013) 1.25

EGF receptor inhibition radiosensitizes NSCLC cells by inducing senescence in cells sustaining DNA double-strand breaks. Cancer Res (2011) 1.24

p190-B RhoGAP regulates mammary ductal morphogenesis. Mol Endocrinol (2003) 1.23

Thy-1 regulates fibroblast focal adhesions, cytoskeletal organization and migration through modulation of p190 RhoGAP and Rho GTPase activity. Exp Cell Res (2004) 1.20

The Drosophila ATM ortholog, dATM, mediates the response to ionizing radiation and to spontaneous DNA damage during development. Curr Biol (2004) 1.19

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers. Cancer Res (2010) 1.13

EGFR ligands exhibit functional differences in models of paracrine and autocrine signaling. Growth Factors (2012) 1.13

GAPs in growth factor signalling. Growth Factors (2005) 1.12

High-throughput lung cancer cell line screening for genotype-correlated sensitivity to an EGFR kinase inhibitor. Methods Enzymol (2008) 1.11

Phospholipids can switch the GTPase substrate preference of a GTPase-activating protein. J Biol Chem (2003) 1.08

ErbBs in lung cancer. Exp Cell Res (2008) 1.07

An FF domain-dependent protein interaction mediates a signaling pathway for growth factor-induced gene expression. Mol Cell (2005) 1.05

Regulation of Rho and Rac signaling to the actin cytoskeleton by paxillin during Drosophila development. Mol Cell Biol (2005) 1.05

Crosstalk between the p190-B RhoGAP and IGF signaling pathways is required for embryonic mammary bud development. Dev Biol (2007) 1.04

Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agents. Clin Cancer Res (2006) 1.03

Bcl-2/Bcl-xL inhibition increases the efficacy of MEK inhibition alone and in combination with PI3 kinase inhibition in lung and pancreatic tumor models. Mol Cancer Ther (2013) 1.03

p190A RhoGAP is a glycogen synthase kinase-3-beta substrate required for polarized cell migration. J Biol Chem (2008) 1.03

Reduced Erlotinib sensitivity of epidermal growth factor receptor-mutant non-small cell lung cancer following cisplatin exposure: a cell culture model of second-line erlotinib treatment. Clin Cancer Res (2008) 1.01

Drosophila Rho-kinase (DRok) is required for tissue morphogenesis in diverse compartments of the egg chamber during oogenesis. Dev Biol (2006) 0.94

Haploinsufficiency for p190B RhoGAP inhibits MMTV-Neu tumor progression. Breast Cancer Res (2009) 0.93

GEFs in growth factor signaling. Growth Factors (2007) 0.92

Interaction of the EGFR inhibitors gefitinib, vandetanib, pelitinib and neratinib with the ABCG2 multidrug transporter: implications for the emergence and reversal of cancer drug resistance. Biochem Pharmacol (2012) 0.92

Oncogenic shock: turning an activated kinase against the tumor cell. Cell Cycle (2006) 0.91

Explaining the preponderance of Kras mutations in human cancer: An isoform-specific function in stem cell expansion. Cell Cycle (2008) 0.90

Targeted combinatorial therapy of non-small cell lung carcinoma using a GST-fusion protein of full-length or truncated MDA-7/IL-24 with Tarceva. J Cell Physiol (2008) 0.90

Combinatorial treatment of non-small-cell lung cancers with gefitinib and Ad.mda-7 enhances apoptosis-induction and reverses resistance to a single therapy. J Cell Physiol (2007) 0.89

Loss of the Rho GTPase activating protein p190-B enhances hematopoietic stem cell engraftment potential. Blood (2009) 0.88

Neutrophil functions and autoimmune arthritis in the absence of p190RhoGAP: generation and analysis of a novel null mutation in mice. J Immunol (2010) 0.88

ErbB2 Is Necessary for ErbB4 Ligands to Stimulate Oncogenic Activities in Models of Human Breast Cancer. Genes Cancer (2011) 0.88

Rho-LIM kinase signaling regulates ecdysone-induced gene expression and morphogenesis during Drosophila metamorphosis. Curr Biol (2004) 0.88

Distinct but overlapping functions for the closely related p190 RhoGAPs in neural development. Dev Neurosci (2006) 0.87

Rho-kinase regulates tissue morphogenesis via non-muscle myosin and LIM-kinase during Drosophila development. BMC Dev Biol (2006) 0.87

Neurite outgrowth from PC12 cells by basic fibroblast growth factor (bFGF) is mediated by RhoA inactivation through p190RhoGAP and ARAP3. J Cell Physiol (2010) 0.86

EGFR-activating mutations correlate with a Fanconi anemia-like cellular phenotype that includes PARP inhibitor sensitivity. Cancer Res (2013) 0.85

Regulation of RhoGAP specificity by phospholipids and prenylation. Methods Enzymol (2006) 0.84

Regulation of the substrate preference of p190RhoGAP by protein kinase C-mediated phosphorylation of a phospholipid binding site. Biochemistry (2009) 0.84

A rho-binding protein kinase C-like activity is required for the function of protein kinase N in Drosophila development. Genetics (2007) 0.83

Loss of the Ras regulator RASAL1: another route to Ras activation in colorectal cancer. Gastroenterology (2008) 0.78

Cell shape and tissue morphogenesis. Semin Cell Dev Biol (2008) 0.77

Specific biochemical inactivation of oncogenic Ras proteins by nucleoside diphosphate kinase. Cancer Res (2003) 0.76

The Q43L mutant of neuregulin 2β is a pan-ErbB receptor antagonist. Biochem J (2012) 0.76

Regulation of the nucleotide state of oncogenic ras proteins by nucleoside diphosphate kinase. Methods Enzymol (2006) 0.76

[A Kras-specific function in cancer initiation]. Ai Zheng (2008) 0.75

Overcoming acquired resistance to Iressa/Tarceva with inhibitors of a different class. Cell Cycle (2005) 0.75